AI drug development startup Pathos AI closes $237M investment
Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic. Pathos is developing cancer drugs […] The post AI drug development startup…
Tech startup Pathos AI has secured $237 million in funding at a $3 billion valuation, led by pharmaceutical giant Bristol Myers Squibb Co. The Series E round attracted participation from various backers, including AstraZeneca plc, NEA, and General Atlantic. Pathos is leveraging an AI platform called Foundry, which has access to approximately 200 petabytes of oncological data.
The software helps researchers identify the most promising drug candidates and plan clinical trials based on biomarkers. Pathos' CEO, Iker Huerga, emphasizes that Foundry has accelerated the company's ability to identify highly promising clinical assets. The funding will primarily support Pathos' JSKN016 program, aimed at developing a cancer therapy using antibody-drug conjugates.
Pathos will also collaborate with AstraZeneca on an ER PROTAC drug and partner with Tempus AI Inc. to analyze anonymized data from patients with neurological conditions. The capital raised will be used to advance Pathos' drug development efforts and improve clinical trial processes.
Written by urgent.news from SiliconANGLE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
